Gilead Sciences (GILD) Free Cash Flow (2009 - 2026)

Gilead Sciences has reported Free Cash Flow for 18 years, with the latest figure at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 46.82% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $10.2 billion (up 3.92% YoY), and the FY2025 full-year result was $9.5 billion, down 8.24% from the prior year.
• Free Cash Flow for Q1 2026 stood at $2.4 billion, down from $3.1 billion in the prior quarter.
• The five-year high for Free Cash Flow was $4.2 billion in Q3 2024, with the low at $720.0 million in Q2 2025.
• Historically, Free Cash Flow has averaged $2.2 billion across 5 years, with a median of $2.1 billion in 2024.
• The largest YoY upside for Free Cash Flow was 155.24% in 2024 against a maximum downside of 45.66% in 2024.
• Gilead Sciences' Free Cash Flow stood at $2.4 billion in 2022, then retreated by 18.11% to $2.0 billion in 2023, then surged by 44.73% to $2.8 billion in 2024, then rose by 10.4% to $3.1 billion in 2025, then slipped by 22.26% to $2.4 billion in 2026.
• The last three Free Cash Flow figures came in at $2.4 billion (Q1 2026), $3.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.